Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

Alexander Vugler¹, James O'connell², Mai Anh Nguyen³, Dietmar Weitz⁴, Thomas Leeuw⁵, Elizabeth Hickford⁶, Alexander Verbitsky⁷, Xiaoyou Ying⁷, Markus Rehberg⁸, Bruce Carrington², Mark Merriman¹, Andrew Moss⁹, Jean-Marie Nicolas¹⁰, Phil Stanley¹, Sara Wright¹¹, Tim Bourne¹², Yann Foricher¹³, Zhaoning Zhu¹⁴, Daniel Brookings¹⁴, Helen Horsley¹⁴, Jag Heer¹⁴, Laurent Schio¹³, Matthias Herrmann⁵, Srinivas Rao⁷, Markus Kohlmann¹⁵, Peter Florian⁵

Affiliations

¹ Immunology Therapeutic Area, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
² Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
³ Sanofi R&D, TMED Pharmacokinetics Dynamics and Metabolism, Frankfurt am Main, Germany.
⁴ Sanofi R&D, Drug Metabolism and Pharmacokinetics, Frankfurt am Main, Germany.
⁵ Sanofi R&D, Type 1/17 Immunology, Immunology and Inflammation Research TA, Frankfurt, Germany.
⁶ Development Science, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
⁷ Sanofi R&D, Translation In vivo Models, Cambridge, MA, United States.
⁸ Sanofi R&D, Translational Disease Modelling, Frankfurt am Main, Germany.
⁹ Translational Medicine Immunology, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹⁰ Development Science, Drug Metabolism and Pharmacokinetics, UCB Pharma, Braine-I'Alleud, Belgium.
¹¹ Early PV Missions, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹² Milvuswood Consultancy, Penn, United Kingdom.
¹³ Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France.
¹⁴ Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹⁵ Sanofi R&D, Early Clinical Development, Therapeutic Area Immunology and Inflammation, Frankfurt am Main, Germany.

PMID: 39478966
PMCID: PMC11523126
DOI: 10.3389/fphar.2024.1479557

Published Erratum

Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

Alexander Vugler et al. Front Pharmacol. 2024.

. 2024 Oct 16:15:1479557.

doi: 10.3389/fphar.2024.1479557. eCollection 2024.

Authors

Affiliations

¹ Immunology Therapeutic Area, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
² Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
³ Sanofi R&D, TMED Pharmacokinetics Dynamics and Metabolism, Frankfurt am Main, Germany.
⁴ Sanofi R&D, Drug Metabolism and Pharmacokinetics, Frankfurt am Main, Germany.
⁵ Sanofi R&D, Type 1/17 Immunology, Immunology and Inflammation Research TA, Frankfurt, Germany.
⁶ Development Science, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
⁷ Sanofi R&D, Translation In vivo Models, Cambridge, MA, United States.
⁸ Sanofi R&D, Translational Disease Modelling, Frankfurt am Main, Germany.
⁹ Translational Medicine Immunology, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹⁰ Development Science, Drug Metabolism and Pharmacokinetics, UCB Pharma, Braine-I'Alleud, Belgium.
¹¹ Early PV Missions, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹² Milvuswood Consultancy, Penn, United Kingdom.
¹³ Sanofi R&D, Integrated Drug Discovery, Vitry-sur-Seine, France.
¹⁴ Global Chemistry, Discovery Sciences, PV Early Solutions, UCB Pharma, Slough, United Kingdom.
¹⁵ Sanofi R&D, Early Clinical Development, Therapeutic Area Immunology and Inflammation, Frankfurt am Main, Germany.

PMID: 39478966
PMCID: PMC11523126
DOI: 10.3389/fphar.2024.1479557

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.1037983.].

Keywords: TNF; TNF trimer; immunogenicity; rheumatoid arthritis; small molecule.

Copyright © 2024 Vugler, O’connell, Nguyen, Weitz, Leeuw, Hickford, Verbitsky, Ying, Rehberg, Carrington, Merriman, Moss, Nicolas, Stanley, Wright, Bourne, Foricher, Zhu, Brookings, Horsley, Heer, Schio, Herrmann, Rao, Kohlmann and Florian.

PubMed Disclaimer

Conflict of interest statement

AV, JO'C, MN, DW, TL, EH, AVe, XY, MR, BC, MM, AM, J-MN, PS, SW, YF, ZZ, DB, HH, JH, LS, MH, SR, MK, and PF are either employees of UCB Pharma or Sanofi and may hold stock of the respective organizations. PF was employed by Sanofi-Aventis Deutschland GmbH at the time the work of the manuscript was conducted. He is now an employee of Boehringer Ingelheim Vetmedica GmbH. TB was employed by Milvuswood Consultancy. The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Erratum for

An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Vugler A, O'Connell J, Nguyen MA, Weitz D, Leeuw T, Hickford E, Verbitsky A, Ying X, Rehberg M, Carrington B, Merriman M, Moss A, Nicholas JM, Stanley P, Wright S, Bourne T, Foricher Y, Zhu Z, Brookings D, Horsley H, Heer J, Schio L, Herrmann M, Rao S, Kohlmann M, Florian P. Vugler A, et al. Front Pharmacol. 2022 Nov 16;13:1037983. doi: 10.3389/fphar.2022.1037983. eCollection 2022. Front Pharmacol. 2022. PMID: 36467083 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Frontiers Media SA
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

Affiliations

Corrigendum: An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

Authors

Affiliations

Abstract

Conflict of interest statement

Erratum for

Publication types

LinkOut - more resources

Full Text Sources